KuhleJBarroCAndreassonU, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med2016; 54(10): 1655–1661.
2.
DisantoGBarroCBenkertP, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of Neurology2017; 81: 857–870.
3.
KuhleJDisantoGLorscheiderJ, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology2015; 84(16): 1639–1643.
4.
NovakovaLZetterbergHSundstromP, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology2017; 89(22): 2230–2237.
5.
LeppertDKuhleJSerumNfLlevels should be used to monitor multiple sclerosis evolution – Yes. Mult Scler2019. Epub ahead of print. DOI: 10.1177/1352458519872921.
6.
MyhrKMTorkildsenO.SerumNFLlevels should be used to monitor multiple sclerosis evolution – No. Mult Scler2019. Epub ahead of print. DOI: 10.1177/1352458519872891.
7.
BarroCBenkertPDisantoG, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain2018; 141(8): 2382–2391.
8.
CantoEBarroCZhaoC, et al. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol. Epub ahead of print 12 August 2019. DOI: 10.1001/jamaneurol.2019.2137.
9.
ChitnisTGonzalezCHealyBC, et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol2018; 5(12): 1478–1491.
10.
ShahimPZetterbergHTegnerY, et al. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology2017; 88(19): 1788–1794.
